HCPCS Code S0115: Deleted bortezomib billing code

HCPCS Code S0115 is a deleted Level II S-code that described bortezomib, 3.5 mg, billed to Medicaid and some commercial payers but never to Medicare. Indeed, it is no longer valid, and any claim that carries it today is denied as an invalid code. Instead, Velcade, the reference bortezomib product, now bills under J9041 at 35 units per 3.5 mg vial. Meanwhile, bortezomib from other manufacturers uses J9046, J9048, J9049 or J9051, matched to the NDC.

Coders still meet S0115 in legacy chargemasters, retrospective audits and old remittance reports. Specifically, this guide covers its descriptor, the unit change, the current codes, and how to correct or defend historical claims.

Found our content helpful?

Key takeaways

HCPCS Code S0115 described bortezomib, 3.5 mg, and is a deleted S-code that Medicare never paid.

S-codes are maintained by the Blue Cross Blue Shield Association, so S0115 was billed only to Medicaid and commercial payers.

J9041 is the current code for Velcade only, and its unit is 0.1 mg, so a 3.5 mg vial bills as 35 units.

Bortezomib from other manufacturers bills under J9046, J9048, J9049 or J9051, matched to the NDC. The old catch-all code, J9044, was deleted 12/31/2022.

Claims sent with S0115 after its deletion are denied as invalid, and only a new or corrected claim with the current code fixes them.

HCPCS Code S0115: official descriptor and deleted status

HCPCS Code S0115 was a Level II temporary S-code with the official descriptor “Bortezomib, 3.5 mg.” S-codes are maintained by the Blue Cross Blue Shield Association, not the HCPCS National Panel, and are not payable by Medicare. However, they still appear in the HCPCS Level II codes that the Centers for Medicare and Medicaid Services (CMS) publishes. As a result, traditional Medicare Fee-for-Service never processed a claim under S0115.

The code is now listed as deleted across major code references, including the AAPC HCPCS code database. Therefore, submitting it on a claim today returns an invalid-code denial regardless of payer. Instead, J9041 is the current code for Velcade.

Why S0115 was deleted and when

S0115 was deleted from the HCPCS code set, and J9041 is the current Velcade code. Meanwhile, bortezomib from other manufacturers now has its own manufacturer-specific codes. Therefore, verify the precise deletion effective date against the CMS HCPCS alpha-numeric file for the applicable year, since the file is updated annually.

What deletion means operationally:

• First, claims submitted with S0115 after the deletion date return an invalid-code denial from all payers, including Medicaid managed care plans that previously accepted the code.
• Second, chargemasters in EHR and billing systems that still carry S0115 must be updated. Specifically, Velcade maps to J9041, and other bortezomib products map to the code that matches their NDC.
• Third, any remittance advice referencing S0115 in a denial reason relates to a historical claim, not a currently billable service.
• Payers running retrospective audits may flag S0115 claims submitted before the deletion date for documentation review. In fact, the flag concerns the records, not the code being invalid at time of service.

Crosswalk: J9041 and the current bortezomib codes

J9041 is the current HCPCS code for Velcade, with the descriptor “Injection, bortezomib (Velcade), 0.1 mg.” However, it covers the reference product only. Bortezomib from other manufacturers bills under J9046, J9048, J9049 or J9051, and the NDC on the vial decides which one applies. In addition, the old not-otherwise-specified code, J9044, was deleted 12/31/2022.

The crosswalk from S0115 carries one critical operational change: the unit of service. S0115 was billed per 3.5 mg vial, while J9041 is billed per 0.1 mg. For example, a single 3.5 mg vial of Velcade equals 35 units of J9041. As a result, billing only 1 unit for a full vial underbills by a factor of 35 and causes underpayment.

Verify J9041 reimbursement rates against the current CMS ASP drug pricing file. In addition, Medicare reimburses separately payable drugs at ASP+6%, and those rates update quarterly. The decision below shows which code a bortezomib line takes, based on the date of service and the NDC.

What S0115 covered: inclusions and exclusions

When S0115 was active, it covered the drug acquisition cost for one 3.5 mg vial of bortezomib. Notably, the code did not bundle administration, supportive care, or anti-emetic premedicants. Instead, billers paired S0115 with a separate CPT administration code for the injection itself, chosen by route and setting.

Drug-only HCPCS codes like S0115 cover the product, not the service around it. In fact, that split runs through the whole medical billing workflow for oncology drugs.

• Included: Bortezomib drug cost per 3.5 mg vial, billed once per vial dispensed or administered.
• Excluded: IV administration, subcutaneous administration, hydration, anti-emetics, and monitoring services (each requires its own CPT code).
• Settings: Physician office, hospital outpatient, and infusion practice, with setting-specific modifiers applied as the payer required.
• Indications: Multiple myeloma and mantle cell lymphoma were the FDA-approved indications at the time, per the VELCADE prescribing information. In addition, off-label use required separate prior authorization documentation.

Medicare and payer coverage under S0115

Traditional Medicare Fee-for-Service never covered S0115. S-codes are maintained by the Blue Cross Blue Shield Association, not the HCPCS National Panel, and are not payable by Medicare. Therefore, submitting S0115 to Medicare would have produced a non-covered service denial regardless of the date of service.

The payers that accepted S0115 historically were mainly state Medicaid programs and commercial insurers that adopted HCPCS S-codes into their own coverage policies. However, coverage terms varied by payer and plan year.

Common coding errors and claim denials for S0115

S0115 denials fell into five patterns. Overall, recognizing them helps billers correct legacy claims and avoid repeating them with the current codes. Good denial management depends on categorizing root causes, not just resubmitting rejected claims.

• Submitting S0115 after the deletion date. As a result, claims land as invalid-code denials. Appeals don’t resolve this. Instead, submit a new or corrected claim with the current code and the corrected unit count.
• Incorrect unit count. Billers who crossed over to J9041 but kept the S0115 unit convention (1 unit per vial) consistently underbilled. For example, a 3.5 mg vial equals 35 units of J9041.
• Missing or incorrect diagnosis code. S0115 required a supporting ICD-10 diagnosis code for multiple myeloma or mantle cell lymphoma. As a result, claims without an oncology diagnosis, or with an unrelated one, were denied for lack of medical necessity.
• Submitting S0115 to Medicare. Medicare never covered S-codes. In fact, this denial type appeared often in mixed-payer practices, where staff sent Medicare the same S0115 code they used for Medicaid.
• Missing NDC number. Medicaid programs require the National Drug Code (NDC) on physician-administered drug claims, under the Deficit Reduction Act of 2005 (section 6002) and state rules. Additionally, many commercial payers require it too. In contrast, Medicare Part B does not generally require an NDC on J-code lines. Consequently, S0115 claims without a valid NDC were rejected at the clearinghouse or denied by the payer.

Neighboring codes often confused with S0115

Bortezomib billing intersects with several related codes. Specifically, the table below clarifies when each applies so billers can make the right selection in current practice.

Documentation requirements when bortezomib was billed under S0115

Payers that accepted S0115 required specific documentation to validate the claim. Indeed, these requirements still matter when responding to retrospective audits on historical S0115 claims. The billing compliance requirements for oncology drugs were stricter than for routine services.

• ICD-10 diagnosis code. A valid oncology diagnosis was required. For multiple myeloma, this was typically C90.00-C90.02 (depending on remission status). For mantle cell lymphoma, it was C83.10-C83.19 (depending on site). In addition, the diagnosis code had to match the patient’s documented clinical condition.
• NDC number. Medicaid programs required the National Drug Code for the specific bortezomib product on the claim line. Specifically, the rule comes from the Deficit Reduction Act of 2005 (section 6002) and state rules. In addition, many commercial payers required it as well. In contrast, Medicare Part B does not generally require an NDC on J-code lines.
• Drug lot number. Many payers also required the lot number from the vial to support drug traceability, particularly for high-cost oncology agents subject to audit.
• Quantity administered vs. quantity ordered. Documentation needed to reflect the dose given, not just the ordered dose. For example, dose reductions due to toxicity had to be reflected in both the medical record and the units billed.
• Prior authorization number. When the plan required prior authorization, the authorization number had to appear on the claim. Consequently, missing prior auth references caused routine denials even for otherwise clean claims.

How to handle old claims or audits referencing S0115

Billers who meet S0115 in retrospective audits or legacy EHR systems need a structured approach. The code is valid for claims with a date of service inside its active period. However, it is not valid for any claim submitted after its deletion date. Apply clean claim submission standards when correcting or resubmitting any historical bortezomib claim.

• Identify the date of service. Confirm whether the date of service predates the deletion. If yes, S0115 was the correct code at time of service. Otherwise, the claim should never have been submitted with S0115.
• Correct claims submitted post-deletion. File a corrected claim (frequency code 7) that replaces S0115 with the current code. For Velcade, that is J9041, with units changed from 1 per vial to 35 per 3.5 mg vial. For other bortezomib products, use the code that matches the NDC. In addition, include the original date of service and a brief remark explaining the correction.
• Respond to audit findings referencing S0115. If an audit flags a historical S0115 claim for documentation review, gather the original encounter notes, NDC, lot number, and ICD-10 code. In fact, the claim was valid if it predates deletion, so state that clearly in the appeal letter.
• Update your chargemaster. Any charge description master item that still maps bortezomib to S0115 must be updated. Specifically, map Velcade to J9041 in 0.1 mg units and other products to their NDC-matched codes. Indeed, a stale chargemaster is how S0115 keeps slipping onto current dates of service.
• Check your EHR drug database. EHR drug-code mapping tables may still associate VELCADE with S0115. Then, confirm with your vendor that Velcade maps to J9041 and that other bortezomib NDCs map to their own codes.

How claims software keeps bortezomib billing accurate

The errors above usually start before a claim is built. For example, a chargemaster still mapped to S0115 is one source. Similarly, a unit count copied from the per-vial convention, or a Medicaid line with no NDC, reaches the payer just as easily.

Pabau, the practice management platform we build, keeps the treatment note, the invoice and the insurance claim on one patient record. Its claims management software submits claims electronically and tracks the status of each one. When a payer rejects a line, your billing team can correct and resubmit it from the original visit.

The result is a claim history you can defend. For example, paid, rejected and corrected bortezomib claims sit against the visit they came from when an auditor asks.

Submit and track drug claims with Pabau

Pabau keeps the visit, the invoice and the insurance claim on one patient record, then submits the claim and tracks its status. Your billing team sees which bortezomib claims were paid and which need a correction.

Book a demo

Conclusion

Treat S0115 as a historical code with one job left: explaining old claims. Overall, on any current date of service, the NDC decides the code, and for Velcade the unit count decides the payment. Get either wrong and the claim is denied or underpaid, even when the drug and the diagnosis are right.

The fix worth doing once is in the chargemaster. Map Velcade to J9041 in 0.1 mg units, map each other bortezomib NDC to its own code, and retire S0115 for new claims. In addition, keep the original records for any S0115 claim still inside an audit window.

Book a demo to see how Pabau submits and tracks drug claims for oncology and infusion practices.

Continue your research

Managing claim denials from deleted or transitional codes? Denial management in healthcare covers root-cause categorization and appeal workflows for billing teams.

Billing Velcade on a current date of service? HCPCS code J9041 covers the current Velcade descriptor, units and documentation.

New to how drug codes fit into a claim? Medical billing fundamentals explains how HCPCS, CPT, and ICD-10 codes work together in the claim lifecycle.

Reading a remittance advice after an S0115 denial? Denial codes in medical billing provides a reference for interpreting remittance advice denial reasons.

Frequently asked questions